Radio and PodcastRadio and PodcastLive Radio & Podcasts
Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis artwork
Science & Medicine

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Jun 3, 20213:00Science & Medicine

Listen to FDA Drug Safety Podcast on due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis

About This Episode

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Cen...

Podcast

This episode belongs to FDA Drug Safety Podcasts.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jun 3, 2021, 3:00 long, audio available.

Related Episodes

Continue listening to more episodes from FDA Drug Safety Podcasts.

Questions About This Episode

What is Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis about?

Listen to FDA Drug Safety Podcast on due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis

Where can I listen to Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis?

You can listen to Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis from?

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.

How long is this episode?

This episode is 3:00 long.

When was this episode published?

This episode was published on Jun 3, 2021.

Can I save Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from FDA Drug Safety Podcasts?

Yes. This page shows related episodes from FDA Drug Safety Podcasts when more episodes are available from the podcast feed.

Quick Answers About This Episode

Where can I listen to Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis?

You can listen to Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis on this page when the episode audio is available from the podcast feed.

Which podcast is this episode from?

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis is from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.

What are the episode details?

Published Jun 3, 2021 and 3:00 long